Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden

Authors

  • Giuseppe Fallara Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita‐Salute San Raffaele University, Milan, Italy; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Ingela Franck Lissbrant Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
  • Johan Styrke Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
  • Francesco Montorsi Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita‐Salute San Raffaele University, Milan, Italy
  • Rolf Gedeborg Department of Surgical Sciences, Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden
  • Fredrik Sandin Regional Cancer Centre, Uppsala/Örebro, Uppsala University Hospital, Uppsala, Sweden
  • Pär Stattin Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

DOI:

https://doi.org/10.1080/0284186X.2020.1847321

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2021-01-02

How to Cite

Fallara, G., Franck Lissbrant, I., Styrke, J., Montorsi, F., Gedeborg, R., Sandin, F., & Stattin, P. (2021). Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncologica, 60(1), 56–60. https://doi.org/10.1080/0284186X.2020.1847321

Issue

Vol. 60 No. 1 (2021): Acta Oncologica

Section

Articles

License

Copyright (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.